Registration Dossier

Toxicological information

Acute Toxicity: oral

Currently viewing:

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Test procedure according to national standards; report with limited detail.

Data source

Referenceopen allclose all

Reference Type:
study report
Title:
Unnamed
Year:
1981
Reference Type:
review article or handbook
Title:
Unnamed
Year:
2004
Report Date:
2004

Materials and methods

Test guideline
Qualifier:
equivalent or similar to
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
GLP compliance:
no
Test type:
standard acute method
Limit test:
no

Test material

Reference
Name:
Unnamed
Type:
Constituent
Details on test material:
SOURCE: AKZO N.V.
PURITY: Not reported
IMPURITY/ADDITIVE/ETC.: Not reported
ANY OTHER INFORMATION: The test substance Natron Waterglass 40/42 (ratio 2.0) is a clear colourless liquid. Density was 1.39. Concentration not indicated.

Test animals

Species:
rat
Strain:
other: Cpb:Wu; Wistar random
Sex:
male/female
Details on test animals and environmental conditions:
TEST ORGANISMS:
- Strain: Not reported
- Source: The Central Institute for the Breeding of Laboratory Animals TNO, Zeist, Netherlands
- Age: Young adult
- Weight at study initiation: 196-336 g (males), 142-195 (females)

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
not specified
Details on oral exposure:
- Volume administered: 2.50, 3.00, 3.60, 4.32, 5.20 mL/kg
Doses:
3.30, 3.96, 4.75, 5.70, 6.86 g/kg bw
No. of animals per sex per dose:
5
Control animals:
not specified
Details on study design:
- Post dose observation: 14 days after treatment

Results and discussion

Effect levels
Sex:
male/female
Dose descriptor:
LD50
Effect level:
3 400 mg/kg bw

Any other information on results incl. tables

MORTALITY:
- Time of death: Between 5 hours and 2 days after dosing
- Number of deaths at each dose: 
Dose   male     female
3.30    0/5      1/5
3.96    0/5      2/5
4.75    1/5      1/5
5.70    2/5      1/5
6.86    5/5      5/5
CLINICAL SIGNS: Sedation, abdominal discomfort, sluggishness and unconsciousness
NECROPSY FINDINGS: No treatment related gross alterations

Applicant's summary and conclusion